Department of Applied Biosciences, Ghent University, Valentijn Vaerwyckweg 1 - Building C, 9000 Gent, Belgium; Department of Biosystems, KU Leuven, Willem de Croylaan 42, 3001 Leuven, Belgium; Department of Biosystems, KU Leuven, Kasteelpark Arenberg 21, 3001 Leuven, Belgium.
Department of Applied Biosciences, Ghent University, Valentijn Vaerwyckweg 1 - Building C, 9000 Gent, Belgium.
Biotechnol Adv. 2018 May-Jun;36(3):624-640. doi: 10.1016/j.biotechadv.2017.12.009. Epub 2017 Dec 15.
Endolysins and their derivatives have emerged in recent years as a novel class of antibacterials, which have now entered the clinical phases. Their rapid mode-of-action and proteinaceous nature differentiates them from any other class of antibiotics. A key feature of endolysins is their modularity and the opportunities that emerge thereof to customize properties such as specificity, activity, stability and solubility. Extensive protein engineering efforts have expanded the activity spectrum to (pan)drug-resistant Gram-negative bacteria or have improved the activity against Gram-positive pathogens. In addition, specific cell wall binding domains derived from endolysins are exploited for the development of diagnostics.
近年来，内切酶及其衍生物作为一类新型抗菌药物崭露头角，现已进入临床阶段。它们的快速作用模式和蛋白质性质使它们有别于其他任何一类抗生素。内切酶的一个关键特征是其模块化，以及由此产生的定制特性的机会，如特异性、活性、稳定性和溶解度。广泛的蛋白质工程努力扩大了活性谱，涵盖了（泛）耐药革兰氏阴性菌，或提高了对革兰氏阳性病原体的活性。此外，还利用内切酶衍生的特定细胞壁结合结构域来开发诊断方法。
